Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Jul 15, 2023; 15(7): 1182-1199
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1182
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1182
Figure 4 ENTPD1-AS1, NORAD and ZNF460-AS1 may interact with miR-144-3p in gastric cancer.
A: Correlation analysis between miR-144-3p and ENTPD1-AS1; B: Correlation analysis between miR-144-3p and NORAD; C: Correlation analysis between miR-144-3p and ZNF460-AS1; D: Correlation analysis between ENTPD1-AS1 and COL5A2; E: Correlation analysis between NORAD and COL5A2; F: Correlation analysis between ZNF460-AS1 and COL5A2; G: Expression of ENTPD1-AS1 in tumor and normal tissues; H: Expression of NORAD in tumor and normal tissues; I: Expression of ZNF460-AS1 in tumor and normal tissues; J: Overall survival (OS) analysis for ENTPD1-AS1 in gastric cancer (GC); K: OS analysis for NORAD in GC; L: OS analysis for ZNF460-AS1 in GC. Normal: n = 45, tumor: n = 446. P < 0.05 means a significant difference.
- Citation: Yuan HM, Pu XF, Wu H, Wu C. ENTPD1-AS1–miR-144-3p-mediated high expression of COL5A2 correlates with poor prognosis and macrophage infiltration in gastric cancer. World J Gastrointest Oncol 2023; 15(7): 1182-1199
- URL: https://www.wjgnet.com/1948-5204/full/v15/i7/1182.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i7.1182